標(biāo)題: Titlebook: Cancer Regional Therapy; HAI, HIPEC, HILP, IL Yuman Fong,T. Clark Gamblin,Jonathan S. Zager Book 2020 Springer Nature Switzerland AG 2020 L [打印本頁(yè)] 作者: protocol 時(shí)間: 2025-3-21 19:57
書(shū)目名稱Cancer Regional Therapy影響因子(影響力)
作者: 蔓藤圖飾 時(shí)間: 2025-3-21 22:17
https://doi.org/10.1057/9781137010490stemic circulation either by diffusion into the vascular compartment or by absorption through peritoneal lymphatics. In addition, the peritoneal-plasma barrier allows dose intensification providing high concentrations of the therapeutic agent while minimizing systemic toxicity. Traditionally, the se作者: NADIR 時(shí)間: 2025-3-22 03:35 作者: 發(fā)電機(jī) 時(shí)間: 2025-3-22 04:56 作者: transient-pain 時(shí)間: 2025-3-22 10:38 作者: modish 時(shí)間: 2025-3-22 16:16 作者: modish 時(shí)間: 2025-3-22 19:33 作者: Esalate 時(shí)間: 2025-3-23 00:11
Arthur Benz,Stefan Kuhlmann,Dieter Sadowskin from a urachal primary, is an exceedingly rare disease whose pathophysiologic characteristics have mainly been determined by case series. As there is no standard systemic therapy for urachal carcinomatosis, CRS/HIPEC provides a useful treatment strategy, with a median overall survival approaching 作者: gain631 時(shí)間: 2025-3-23 03:34
https://doi.org/10.1007/978-3-030-46420-2tients with colorectal primaries, major complication rates range from 31% to 47% in patients with HI and 11% to 31% in patients without HI. Thirty-day mortality in patients with HI ranges from 0 to 3%, and 0.6% to 5% in patients without HI. Median OS is 13 to 35.3?months in patients with HI, and fro作者: BOLT 時(shí)間: 2025-3-23 09:31
stigation are presented to inform the direction of the field. ..?..Cancer Regional Therapy. summarizes the history, current technology, common procedures, and future prospects in this field and includes procedures from many surgical and interventional radiologic disciplines..978-3-030-28893-8978-3-030-28891-4作者: incite 時(shí)間: 2025-3-23 11:54 作者: 仇恨 時(shí)間: 2025-3-23 15:06
Novel Biological Therapies with Direct Application to the Peritoneal Cavityll-associated antigens in a virus-induced, highly inflammatory tumor micromilieu, whereas ICIs optimize the execution of a systemic antitumoral immune response by releasing the “brakes” of the immune system, thus enabling T cells to kill cancer cells more efficiently. This and similar biotherapeutic作者: 確定方向 時(shí)間: 2025-3-23 19:46 作者: 強(qiáng)行引入 時(shí)間: 2025-3-23 22:53 作者: Brain-Waves 時(shí)間: 2025-3-24 02:29
Data for HIPEC in Colorectal Cancer (T4 Lesions and Metastases)nd HIPEC for advanced colorectal cancer remain high, it is within a range established for other interventions for advanced cancers and has been shown to improve with increased surgeon and institution experience. Though HIPEC was initially introduced for the management of established peritoneal carci作者: Trigger-Point 時(shí)間: 2025-3-24 09:25
Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastasis eft behind after complete cytoreduction of macroscopic PM might be completely eradicated by HIPEC and postoperative chemotherapy..The comprehensive treatment is promising for GC-PM and brings cure in selected patients with PCI less than cutoff level who received complete cytoreduction and HIPEC. Bec作者: Cervical-Spine 時(shí)間: 2025-3-24 11:19 作者: 食料 時(shí)間: 2025-3-24 16:48 作者: 天文臺(tái) 時(shí)間: 2025-3-24 19:51
https://doi.org/10.1057/9781137304483hat can be gained when the immune system is directed to target solid tumors. We also examine the technologies supporting regional delivery and discuss how existing infusion practices are used to treat solid tumors.作者: Ingest 時(shí)間: 2025-3-25 00:19
Regional Gene Therapy for Cancerhat can be gained when the immune system is directed to target solid tumors. We also examine the technologies supporting regional delivery and discuss how existing infusion practices are used to treat solid tumors.作者: Pelago 時(shí)間: 2025-3-25 04:56
Maurizio Atzeni,Pablo Ghiglianis of each device. This chapter presents an overview of the different modalities followed by a discussion of their clinical applications in the liver, focusing on hepatocellular carcinoma and metastases from colon and breast cancer.作者: verdict 時(shí)間: 2025-3-25 09:06 作者: 香料 時(shí)間: 2025-3-25 12:16
Principles of Percutaneous Ablation in the Livers of each device. This chapter presents an overview of the different modalities followed by a discussion of their clinical applications in the liver, focusing on hepatocellular carcinoma and metastases from colon and breast cancer.作者: idiopathic 時(shí)間: 2025-3-25 17:05
Rationale Behind HIPEC/Molecular and Genetic Considerations in HIPECon. Understanding these processes may be crucial to improving patient selection and in developing potential targeted therapies. This chapter focuses on the scientific rationale behind hyperthermic intraperitoneal chemotherapy (HIPEC) as anticancer therapy as well as the molecular and genetic considerations surrounding the use of HIPEC.作者: malign 時(shí)間: 2025-3-25 20:21
Data for HIPEC for Pseudomyxoma Peritonei/Tumors of the Appendixeen applied to this disease and is currently considered the standard-of-care. The aim of this chapter is to summarize existing data on CRS with HIPEC for appendiceal tumors with peritoneal dissemination, including both PMP from mucinous neoplasms and carcinomatosis from appendiceal adenocarcinoma.作者: conservative 時(shí)間: 2025-3-26 03:12
Regional Therapy for the Treatment of Ovarian Cancer: HIPEC and Intraperitoneal Chemotherapyional chemotherapies directly into the abdominal cavity. Further studies will be required to determine specific population of ovarian cancer patients that may best derive benefit from this therapeutic approach.作者: 星球的光亮度 時(shí)間: 2025-3-26 08:13 作者: Inoperable 時(shí)間: 2025-3-26 12:28
Complications of Cytoreductive Surgery and HIPECe. Two of the more feared complications are anastomotic leak and fistula formation; management algorithms for each clinical situation are provided. Detailed knowledge of the components of CRS and whether HIPEC was performed is critical in order to effectively manage complications among this complex patient population.作者: 北極熊 時(shí)間: 2025-3-26 15:12 作者: Anthrp 時(shí)間: 2025-3-26 19:47
on the theory and practice of CRT.This book is a state-of-the-art overview of cancer regional therapy (CRT) for the surgeons and interventional radiologists active in CRT development and research. The goals of this book are 1) to review the theory and practice of cancer regional therapies including 作者: Gossamer 時(shí)間: 2025-3-26 21:47
Methodological Guidelines and Challenges,ize key general issues that form the foundation of uncomplicated postoperative recovery. We will then discuss strategies to prevent common complications. Best available evidence for treatment strategies will be presented as well as potential new directions.作者: Aphorism 時(shí)間: 2025-3-27 02:29
Postoperative Management of Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneize key general issues that form the foundation of uncomplicated postoperative recovery. We will then discuss strategies to prevent common complications. Best available evidence for treatment strategies will be presented as well as potential new directions.作者: Infraction 時(shí)間: 2025-3-27 07:15
Jerzy Wratny,Agata Ludera-Ruszeleen applied to this disease and is currently considered the standard-of-care. The aim of this chapter is to summarize existing data on CRS with HIPEC for appendiceal tumors with peritoneal dissemination, including both PMP from mucinous neoplasms and carcinomatosis from appendiceal adenocarcinoma.作者: 平常 時(shí)間: 2025-3-27 12:48
Governance – A Sociological Perspectiveional chemotherapies directly into the abdominal cavity. Further studies will be required to determine specific population of ovarian cancer patients that may best derive benefit from this therapeutic approach.作者: maladorit 時(shí)間: 2025-3-27 13:59
https://doi.org/10.1057/9781137284594verload, and the physiologic challenges to the cardiopulmonary system and acid base status are ongoing. It is imperative to have an understanding of the chemotherapeutic agents used and their effects on management. Lastly, our Acute Pain Service is actively involved in the intraoperative and postoperative management of pain.作者: 辭職 時(shí)間: 2025-3-27 19:59 作者: blight 時(shí)間: 2025-3-27 22:59
The Basis of Regional Therapy, Pharmacology, Hyperthermia, and Drug Resistance cells in peritoneal implants, agents must first reach the target. The inability of the drug to reach the target is a basic mechanism of drug resistance. Chemotherapy delivered intravenously encounters the following resistances: (a) distribution through vascular space, (b) transport across microvasc作者: 易于交談 時(shí)間: 2025-3-28 02:38
Novel Biological Therapies with Direct Application to the Peritoneal Cavityich is hard to combat despite a large variety of conventional treatment modalities being currently at hand. In this context, novel biological therapies which can be directly applied to the peritoneal cavity open up urgently needed new perspectives. Such biotherapies do not display any cross-resistan作者: dysphagia 時(shí)間: 2025-3-28 07:23 作者: 善于騙人 時(shí)間: 2025-3-28 12:59
Principles of Percutaneous Ablation in the Liversolid organs and soft tissue. In well-selected cases, ablation can provide long-term survival on par with resection; furthermore, the addition of intraoperative ablation has increased the number of patients amenable to curative resection. There are several different modalities commercially available作者: octogenarian 時(shí)間: 2025-3-28 18:38 作者: META 時(shí)間: 2025-3-28 22:44
Historical Perspective for Regional Peritoneal Therapy: HIPEC, EPIC, and Port-Based Therapyc malignancy, and malignant peritoneal mesothelioma. The methodology for administering the chemotherapy into the peritoneal space varies widely. The selection factors that are required for rational application of these treatments are necessary for benefit to occur. Hyperthermic intraperitoneal chemo作者: enflame 時(shí)間: 2025-3-29 01:17 作者: Fabric 時(shí)間: 2025-3-29 06:38 作者: 萬(wàn)花筒 時(shí)間: 2025-3-29 07:34 作者: flammable 時(shí)間: 2025-3-29 13:19
Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastasis eritoneal/systemic chemotherapy (NIPS), extensive intraperitoneal lavage (EIPL), and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from gastric cancer (GC-PM). Combination of these treatments is called “comprehensive treatment.” The survival rate after comprehensive tre作者: 保守黨 時(shí)間: 2025-3-29 19:06
Regional Therapy for the Treatment of Ovarian Cancer: HIPEC and Intraperitoneal Chemotherapyintravenous-based chemotherapies and targeted agents. However, there is strong rationale for targeting the abdominal/pelvic cavity as ovarian cancer typically involves the peritoneal lining and surfaces of organs in the abdominal and pelvic cavity. Recent clinical trials have supported utilizing reg作者: 謊言 時(shí)間: 2025-3-29 20:28
Mesothelioma and Miscellaneous Disease Processeseal studding and/or ascites. Although usually advanced disease is found within the peritoneal cavity, spread beyond the abdomen is uncommonly encountered. Although advances in systemic chemotherapy have been made, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have作者: 冷淡周邊 時(shí)間: 2025-3-30 01:11
Anesthetic Considerations for Regional Therapies confined to the liver pose considerable anesthetic challenges. They are lengthy and complex procedures, involving significant fluid and blood loss, evolving theories on the management of fluids, intraoperative hyperthermia, the metabolic changes, intra-abdominal hypertension associated with fluid o作者: Ebct207 時(shí)間: 2025-3-30 04:42 作者: 迅速飛過(guò) 時(shí)間: 2025-3-30 09:48 作者: 監(jiān)禁 時(shí)間: 2025-3-30 16:06 作者: CROAK 時(shí)間: 2025-3-30 16:48 作者: 喃喃訴苦 時(shí)間: 2025-3-30 21:47 作者: 拉開(kāi)這車床 時(shí)間: 2025-3-31 02:57 作者: 排斥 時(shí)間: 2025-3-31 08:01 作者: employor 時(shí)間: 2025-3-31 09:45 作者: 邊緣帶來(lái)墨水 時(shí)間: 2025-3-31 17:12
Maurizio Atzeni,Pablo Ghiglianisolid organs and soft tissue. In well-selected cases, ablation can provide long-term survival on par with resection; furthermore, the addition of intraoperative ablation has increased the number of patients amenable to curative resection. There are several different modalities commercially available作者: Bombast 時(shí)間: 2025-3-31 19:24 作者: 離開(kāi) 時(shí)間: 2025-4-1 01:12
